Analysts Set Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Price Target at $28.00

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) have been given an average rating of “Reduce” by the six research firms that are presently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating and three have given a hold rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $28.00.

A number of brokerages have recently commented on FMS. Weiss Ratings cut Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 5th. Zacks Research cut shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Truist Financial set a $28.00 target price on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Monday, January 5th. Bank of America lowered Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating in a research note on Wednesday, October 15th. Finally, Wall Street Zen raised Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Institutional investors and hedge funds have recently made changes to their positions in the business. Hennessy Advisors Inc. purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the second quarter valued at $11,479,000. Bank of America Corp DE grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 279.7% in the second quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock valued at $9,637,000 after purchasing an additional 248,477 shares in the last quarter. Pzena Investment Management LLC raised its stake in Fresenius Medical Care AG & Co. KGaA by 1.0% during the third quarter. Pzena Investment Management LLC now owns 14,816,852 shares of the company’s stock worth $390,128,000 after purchasing an additional 153,870 shares during the period. Qube Research & Technologies Ltd raised its position in Fresenius Medical Care AG & Co. KGaA by 175.3% in the second quarter. Qube Research & Technologies Ltd now owns 199,563 shares of the company’s stock valued at $5,702,000 after purchasing an additional 127,073 shares during the period. Finally, Arlington Capital Management Inc. acquired a new position in Fresenius Medical Care AG & Co. KGaA in the second quarter valued at about $2,569,000. 8.37% of the stock is currently owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of NYSE:FMS opened at $22.00 on Friday. Fresenius Medical Care AG & Co. KGaA has a 52 week low of $21.02 and a 52 week high of $30.46. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.36. The firm has a 50 day simple moving average of $23.39 and a 200 day simple moving average of $25.01.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its earnings results on Tuesday, November 4th. The company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.05. The company had revenue of $5.73 billion for the quarter, compared to analyst estimates of $4.72 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 7.42% and a net margin of 3.72%. Research analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.